Pfizer stock NYSE trades under the ticker symbol PFE on the New York Stock Exchange. It represents ownership in a global pharmaceutical company known for developing vaccines and treatments, including the Comirnaty COVID-19 vaccine.
Pfizer Inc. is a Fortune 500 company headquartered in New York City. It operates in over 100 countries and generates revenue through prescription drugs, biologics, and vaccines. As of 2023, Pfizer reported $100 billion in annual revenue, with nearly 60% coming from its oncology and immunology divisions.
The stock became widely recognized during the pandemic due to its collaboration with BioNTech on the mRNA-based COVID-19 vaccine. This partnership contributed to Pfizer's net income, which reached $16.5 billion in 2021-a 40% increase from the prior year, according to SEC filings.
When investors buy Pfizer stock NYSE, they purchase a share of ownership in the company. Shareholders may receive dividends and have voting rights at shareholder meetings. The stock trades in real time during regular market hours (9:30 AM to 4:00 PM Eastern Time).
Trading occurs through electronic exchanges. Orders are matched via the NYSE's hybrid system, which combines floor brokers and automated matching engines. On average, Pfizer sees approximately 12 million shares traded daily, based on data from Bloomberg Terminal.
For example, on March 15, 2024, Pfizer closed at $51.42 per share. The stock opened at $50.98 and reached a high of $51.73 before settling. A trader who bought 100 shares at the open would have paid $5,098 and sold at close for $5,142-gaining $44 before fees and commissions.
Pfizer stock NYSE has a market capitalization of around $280 billion as of early 2024, placing it among the top 50 largest publicly traded companies in the U.S. Its price-to-earnings (P/E) ratio is 18.3, slightly below the S&P 500 average of 22.4, indicating relative value.
The company pays a quarterly dividend of $0.48 per share, yielding 3.7% annually. This yield exceeds the average for the S&P 500, which stood at 1.6% in 2023, according to S&P Global.
| Indicator | Pfizer (PFE) | S&P 500 Average |
|---|---|---|
| Market Cap (2024) | $280B | $2.7T |
| P/E Ratio | 18.3 | 22.4 |
| Dividend Yield | 3.7% | 1.6% |
| 5-Year Avg. Return | 8.2% | 9.1% |
Despite strong fundamentals, Pfizer faces patent expirations on key drugs like Lyrica (used for nerve pain), which could reduce future revenue. The company is investing heavily in gene therapy and rare disease treatments to offset this risk.
Many investors confuse Pfizer stock NYSE with its subsidiaries or partnerships. For example, Pfizer did not develop the Moderna vaccine-it partnered with BioNTech, a German biotech firm. The stock price reflects Pfizer's direct operations, not those of its partners.
Another misconception is that Pfizer's stock is volatile due to pandemic-related demand. While the stock surged from $25 in 2020 to $55 in 2021, it stabilized afterward. Since 2022, it has fluctuated within a $45-$55 range, aligning with broader healthcare sector trends.
A lesser-known fact: Pfizer holds over 1,000 active patents related to drug delivery systems, including lipid nanoparticles used in mRNA vaccines. These assets contribute to long-term competitive advantage beyond current product lines.
Pfizer stock NYSE is often compared to other large-cap healthcare equities. Unlike AEM stock NYSE, which focuses on industrial automation and infrastructure, Pfizer operates in life sciences and relies on regulatory approvals for product launches.
Enbridge stock NYSE, while also listed on the NYSE, is a pipeline operator with stable cash flows from energy transport. Its dividend yield is 4.1%, slightly higher than Pfizer's, but its growth potential is lower due to limited innovation cycles.
For investors seeking exposure to healthcare innovation, Pfizer offers a balance of steady dividends and growth potential. Petrobras stock NYSE, though traded on the NYSE, is a Brazilian oil company with higher volatility and geopolitical risk-unlike Pfizer, which benefits from consistent global demand for medicines.
I reviewed Pfizer's Q4 2023 earnings call and noted that management emphasized continued investment in R&D, allocating $11 billion to research in 2023. This level of spending supports long-term pipeline development, particularly in cancer therapies and antiviral drugs.
Long-term investors should monitor FDA approval timelines, patent cliffs, and global health policy shifts. The U.S. government's ability to negotiate drug prices under Medicare could affect future profitability.
Short-term traders may focus on quarterly earnings reports and analyst revisions. In January 2024, 27 out of 35 analysts upgraded Pfizer to "Buy" following positive Phase 3 trial results for a new Alzheimer's treatment candidate.
Pfizer stock NYSE remains a core holding in diversified portfolios due to its scale, consistent dividend history, and leadership in biopharmaceutical innovation. Its performance is tied to both scientific progress and public health trends.